cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.17632/m7ds6pkxd3.1
title: Flood Damage Risk Mapping along the River Niger (2024-2025)

description: This dataset contains information used for the quantitative estimation of flood risk along the Niger River upstream of the city of Niamey, Niger. The data was collected as part of the SLAPIS Project through field surveys, interviews with farmers and processing of data extracted from satellite images. The dataset includes three folders:
1. Agriculture: This folder includes (i) land cover classes for rice in irrigated perimeters, pond rice, horticulture, pumpkins, and sweet potatoes; (ii) sample fields for each land cover class, where the crops and their inundation status were verified on ground as of mid-February 2025.
2. Flood Plain: This folder includes (i) the inundated areas as of August 20, 2024, and February 16, 2025, extracted from Sentinel-2 imagery using the Modified Normalized Difference Water Index (MNDWI); (ii) Ground Control Points of the water edge detected by GPS.
3. Human Settlements: This folder includes (i) the built-up areas of human settlements within a 1 km strip from the Niger Riverbank and within river islands. The information was extracted by visual photointerpretation of very high-resolution satellite image as of February 2024 accessible on Google Earth; (ii) buildings located within the inundated area as of August 20, 2024.
DOI: 10.34816/efa.archives.1217215
title: Délos-FRV_B15-004-Fondations, détail

description: Référence : FRV_B15-004<br />Publication(s) : Inédit<br />Domaine : Architecture; Fouille<br />
DOI: 10.34816/efa.archives.1217216
title: Délos-FRV_B16_01-001-Base du Dôdékathéon située au sud-ouest de l'Agora des Italiens

description: Référence : FRV_B16_01-001<br />Publication(s) : Inédit<br />Domaine : Architecture<br />
DOI: 10.34816/efa.archives.1217217
title: Délos-FRV_B16_01-002-Pôrinos Naos, vue d'ensemble

description: Référence : FRV_B16_01-002<br />Publication(s) : Inédit<br />Domaine : Architecture<br />
DOI: 10.34816/efa.archives.1217218
title: Délos-FRV_B16_01-003-Jonction entre les Propylées sud et le mur sud de l'Oikos des Naxiens

description: Référence : FRV_B16_01-003<br />Publication(s) : Inédit<br />Domaine : Architecture<br />
DOI: 10.34816/efa.archives.1217219
title: Délos-FRV_B16_01-004-Prostoôn, vue d'ensemble

description: Référence : FRV_B16_01-004<br />Publication(s) : Inédit<br />Domaine : Architecture<br />
DOI: 10.34816/efa.archives.1217220
title: Délos-FRV_B16_01-005-Trésor 5, vue d'ensemble

description: Référence : FRV_B16_01-005<br />Publication(s) : Inédit<br />Domaine : Architecture<br />
DOI: 10.15468/dl.jjb9ch
title: Occurrence Download

description: A dataset containing 9743 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Cosmos sulphureus Cav.",
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 {
 "or" : [
 "CoordinateUncertaintyInMeters is less than 10000",
 "CoordinateUncertaintyInMeters is null"
 ]
 }
 ]
}

 The dataset includes 9743 records from 282 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0018848-250310093411724/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rd7z3r
title: Occurrence Download

description: A dataset containing 13817 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is United States of America",
 "OccurrenceStatus is Present",
 "PublishingOrg is 4f1bbd8f-a4ad-40dd-b098-283792d3679b"
 ]
}

 The dataset includes 13817 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0018847-250310093411724/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17632/62dtcgmfpf.1
title: The combination of capecitabine and fecal microbiota transplantation in colorectal cancer treatment: reversing microbial dysbiosis and regulating the intestinal immune microenvironment

description: The significant economic burden of colorectal cancer (CRC) necessitates the development of innovative therapeutic approaches. Interest in the gut microbiota's role in CRC has increased. Capecitabine, as a chemotherapy, may disrupt the balance of the intestinal microbiota. The study investigated the anticancer effects of capecitabine combined with fecal microbiota transplantation (FMT) in a CRC mouse model caused by azoxymethane and dextran sodium sulfate. FMT was achieved with fecal microbiota from healthy mice through enema. Capecitabine decreased the number and diameter of cancer foci in CRC mice, while FMT supplementation had a more noticeable impact, indicated by increased body weight and survival rate. Capecitabine greatly decreased the abundance of harmful bacteria found in CRC mice. These bacteria included Bacteroides, Enterorhabdus, Monoglobus, Rodentibacter, uncultured_rumen_bacterium, Turicibacter, and Streptococcus. The supplement of FMT more effectively reversed the dysbiosis of the gut microbiota in CRC mice, as demonstrated by the ACE and Chao 1 index, PCoA analysis and enhanced biological pathways. Microbial dysbiosis induced immunological dysfunction in CRC mice, indicated by abnormal immune cell recruitment and excessive cytokine production. Capecitabine treatment reduced immune cell infiltration, including CD3+ T cells, CD4+ T cells, and CD49b+ NK cells, as chemotherapy often suppresses the immune system. The supplement of FMT increased the proportion of CD4+ T cells, CD49b+ NK cells, as well as CD8+ T cells and LY6G+ neutrophils, indicating improved immune responses against CRC. Moreover, capecitabine therapy alone reduced the overexpression of IL1a, IL6, IL12a, IL12b, IL17, IL22, FOXP3, STAT3, IFN-γ, TNF-α, TGF-β, GZMA, CXCR4, OPN, PD-1 and PD-L1. FMT supplementation resulted in a higher immune response to CRC as it had a greater inhibitory effect on the overexpression of inflammatory cytokines and enhanced the production of IL10, IFN-γ and CXCR4. These cytokines were positively correlated with Azospirillum_sp._47_25, Romboutsia, Lactococcus, Rikenella_sp._Marseille_P3215 and Turicibacter and negatively correlated with Parabacteroids, unclassified_Oscillospiraceae, Marvinbryantia, unclassified_Clostridia_vadinBB60_group, unclassified_Erysipelatoclostridiaceae, A2, Roseburia, Rikenellaceae_RC9_gut_group, Acetatifactor and unclassified_Clostridia. The combination of capecitabine and FMT is more effective at preventing CRC than capecitabine alone, as it reverses gut microbial abnormalities and boosts immune responses to CRC.
DOI: 10.17632/62dtcgmfpf.2
title: The combination of capecitabine and fecal microbiota transplantation in colorectal cancer treatment: reversing microbial dysbiosis and regulating the intestinal immune microenvironment

description: The significant economic burden of colorectal cancer (CRC) necessitates the development of innovative therapeutic approaches. Interest in the gut microbiota's role in CRC has increased. Capecitabine, as a chemotherapy, may disrupt the balance of the intestinal microbiota. The study investigated the anticancer effects of capecitabine combined with fecal microbiota transplantation (FMT) in a CRC mouse model caused by azoxymethane and dextran sodium sulfate. FMT was achieved with fecal microbiota from healthy mice through enema. Capecitabine decreased the number and diameter of cancer foci in CRC mice, while FMT supplementation had a more noticeable impact, indicated by increased body weight and survival rate. Capecitabine greatly decreased the abundance of harmful bacteria found in CRC mice. These bacteria included Bacteroides, Enterorhabdus, Monoglobus, Rodentibacter, uncultured_rumen_bacterium, Turicibacter, and Streptococcus. The supplement of FMT more effectively reversed the dysbiosis of the gut microbiota in CRC mice, as demonstrated by the ACE and Chao 1 index, PCoA analysis and enhanced biological pathways. Microbial dysbiosis induced immunological dysfunction in CRC mice, indicated by abnormal immune cell recruitment and excessive cytokine production. Capecitabine treatment reduced immune cell infiltration, including CD3+ T cells, CD4+ T cells, and CD49b+ NK cells, as chemotherapy often suppresses the immune system. The supplement of FMT increased the proportion of CD4+ T cells, CD49b+ NK cells, as well as CD8+ T cells and LY6G+ neutrophils, indicating improved immune responses against CRC. Moreover, capecitabine therapy alone reduced the overexpression of IL1a, IL6, IL12a, IL12b, IL17, IL22, FOXP3, STAT3, IFN-γ, TNF-α, TGF-β, GZMA, CXCR4, OPN, PD-1 and PD-L1. FMT supplementation resulted in a higher immune response to CRC as it had a greater inhibitory effect on the overexpression of inflammatory cytokines and enhanced the production of IL10, IFN-γ and CXCR4. These cytokines were positively correlated with Azospirillum_sp._47_25, Romboutsia, Lactococcus, Rikenella_sp._Marseille_P3215 and Turicibacter and negatively correlated with Parabacteroids, unclassified_Oscillospiraceae, Marvinbryantia, unclassified_Clostridia_vadinBB60_group, unclassified_Erysipelatoclostridiaceae, A2, Roseburia, Rikenellaceae_RC9_gut_group, Acetatifactor and unclassified_Clostridia. The combination of capecitabine and FMT is more effective at preventing CRC than capecitabine alone, as it reverses gut microbial abnormalities and boosts immune responses to CRC.
DOI: 10.17632/62dtcgmfpf.3
title: The combination of capecitabine and fecal microbiota transplantation in colorectal cancer treatment: reversing microbial dysbiosis and regulating the intestinal immune microenvironment

description: The significant economic burden of colorectal cancer (CRC) necessitates the development of innovative therapeutic approaches. Interest in the gut microbiota's role in CRC has increased. Capecitabine, as a chemotherapy, may disrupt the balance of the intestinal microbiota. The study investigated the anticancer effects of capecitabine combined with fecal microbiota transplantation (FMT) in a CRC mouse model caused by azoxymethane and dextran sodium sulfate. FMT was achieved with fecal microbiota from healthy mice through enema. Capecitabine decreased the number and diameter of cancer foci in CRC mice, while FMT supplementation had a more noticeable impact, indicated by increased body weight and survival rate. Capecitabine greatly decreased the abundance of harmful bacteria found in CRC mice. These bacteria included Bacteroides, Enterorhabdus, Monoglobus, Rodentibacter, uncultured_rumen_bacterium, Turicibacter, and Streptococcus. The supplement of FMT more effectively reversed the dysbiosis of the gut microbiota in CRC mice, as demonstrated by the ACE and Chao 1 index, PCoA analysis and enhanced biological pathways. Microbial dysbiosis induced immunological dysfunction in CRC mice, indicated by abnormal immune cell recruitment and excessive cytokine production. Capecitabine treatment reduced immune cell infiltration, including CD3+ T cells, CD4+ T cells, and CD49b+ NK cells, as chemotherapy often suppresses the immune system. The supplement of FMT increased the proportion of CD4+ T cells, CD49b+ NK cells, as well as CD8+ T cells and LY6G+ neutrophils, indicating improved immune responses against CRC. Moreover, capecitabine therapy alone reduced the overexpression of IL1a, IL6, IL12a, IL12b, IL17, IL22, FOXP3, STAT3, IFN-γ, TNF-α, TGF-β, GZMA, CXCR4, OPN, PD-1 and PD-L1. FMT supplementation resulted in a higher immune response to CRC as it had a greater inhibitory effect on the overexpression of inflammatory cytokines and enhanced the production of IL10, IFN-γ and CXCR4. These cytokines were positively correlated with Azospirillum_sp._47_25, Romboutsia, Lactococcus, Rikenella_sp._Marseille_P3215 and Turicibacter and negatively correlated with Parabacteroids, unclassified_Oscillospiraceae, Marvinbryantia, unclassified_Clostridia_vadinBB60_group, unclassified_Erysipelatoclostridiaceae, A2, Roseburia, Rikenellaceae_RC9_gut_group, Acetatifactor and unclassified_Clostridia. The combination of capecitabine and FMT is more effective at preventing CRC than capecitabine alone, as it reverses gut microbial abnormalities and boosts immune responses to CRC.
DOI: 10.17632/62dtcgmfpf.4
title: The combination of capecitabine and fecal microbiota transplantation in colorectal cancer treatment: reversing microbial dysbiosis and regulating the intestinal immune microenvironment

description: The significant economic burden of colorectal cancer (CRC) necessitates the development of innovative therapeutic approaches. Interest in the gut microbiota's role in CRC has increased. Capecitabine, as a chemotherapy, may disrupt the balance of the intestinal microbiota. The study investigated the anticancer effects of capecitabine combined with fecal microbiota transplantation (FMT) in a CRC mouse model caused by azoxymethane and dextran sodium sulfate. FMT was achieved with fecal microbiota from healthy mice through enema. Capecitabine decreased the number and diameter of cancer foci in CRC mice, while FMT supplementation had a more noticeable impact, indicated by increased body weight and survival rate. Capecitabine greatly decreased the abundance of harmful bacteria found in CRC mice. These bacteria included Bacteroides, Enterorhabdus, Monoglobus, Rodentibacter, uncultured_rumen_bacterium, Turicibacter, and Streptococcus. The supplement of FMT more effectively reversed the dysbiosis of the gut microbiota in CRC mice, as demonstrated by the ACE and Chao 1 index, PCoA analysis and enhanced biological pathways. Microbial dysbiosis induced immunological dysfunction in CRC mice, indicated by abnormal immune cell recruitment and excessive cytokine production. Capecitabine treatment reduced immune cell infiltration, including CD3+ T cells, CD4+ T cells, and CD49b+ NK cells, as chemotherapy often suppresses the immune system. The supplement of FMT increased the proportion of CD4+ T cells, CD49b+ NK cells, as well as CD8+ T cells and LY6G+ neutrophils, indicating improved immune responses against CRC. Moreover, capecitabine therapy alone reduced the overexpression of IL1a, IL6, IL12a, IL12b, IL17, IL22, FOXP3, STAT3, IFN-γ, TNF-α, TGF-β, GZMA, CXCR4, OPN, PD-1 and PD-L1. FMT supplementation resulted in a higher immune response to CRC as it had a greater inhibitory effect on the overexpression of inflammatory cytokines and enhanced the production of IL10, IFN-γ and CXCR4. These cytokines were positively correlated with Azospirillum_sp._47_25, Romboutsia, Lactococcus, Rikenella_sp._Marseille_P3215 and Turicibacter and negatively correlated with Parabacteroids, unclassified_Oscillospiraceae, Marvinbryantia, unclassified_Clostridia_vadinBB60_group, unclassified_Erysipelatoclostridiaceae, A2, Roseburia, Rikenellaceae_RC9_gut_group, Acetatifactor and unclassified_Clostridia. The combination of capecitabine and FMT is more effective at preventing CRC than capecitabine alone, as it reverses gut microbial abnormalities and boosts immune responses to CRC.
DOI: 10.17632/62dtcgmfpf.5
title: The combination of capecitabine and fecal microbiota transplantation in colorectal cancer treatment: reversing microbial dysbiosis and regulating the intestinal immune microenvironment

description: The significant economic burden of colorectal cancer (CRC) necessitates the development of innovative therapeutic approaches. Interest in the gut microbiota's role in CRC has increased. Capecitabine, as a chemotherapy, may disrupt the balance of the intestinal microbiota. The study investigated the anticancer effects of capecitabine combined with fecal microbiota transplantation (FMT) in a CRC mouse model caused by azoxymethane and dextran sodium sulfate. FMT was achieved with fecal microbiota from healthy mice through enema. Capecitabine decreased the number and diameter of cancer foci in CRC mice, while FMT supplementation had a more noticeable impact, indicated by increased body weight and survival rate. Capecitabine greatly decreased the abundance of harmful bacteria found in CRC mice. These bacteria included Bacteroides, Enterorhabdus, Monoglobus, Rodentibacter, uncultured_rumen_bacterium, Turicibacter, and Streptococcus. The supplement of FMT more effectively reversed the dysbiosis of the gut microbiota in CRC mice, as demonstrated by the ACE and Chao 1 index, PCoA analysis and enhanced biological pathways. Microbial dysbiosis induced immunological dysfunction in CRC mice, indicated by abnormal immune cell recruitment and excessive cytokine production. Capecitabine treatment reduced immune cell infiltration, including CD3+ T cells, CD4+ T cells, and CD49b+ NK cells, as chemotherapy often suppresses the immune system. The supplement of FMT increased the proportion of CD4+ T cells, CD49b+ NK cells, as well as CD8+ T cells and LY6G+ neutrophils, indicating improved immune responses against CRC. Moreover, capecitabine therapy alone reduced the overexpression of IL1a, IL6, IL12a, IL12b, IL17, IL22, FOXP3, STAT3, IFN-γ, TNF-α, TGF-β, GZMA, CXCR4, OPN, PD-1 and PD-L1. FMT supplementation resulted in a higher immune response to CRC as it had a greater inhibitory effect on the overexpression of inflammatory cytokines and enhanced the production of IL10, IFN-γ and CXCR4. These cytokines were positively correlated with Azospirillum_sp._47_25, Romboutsia, Lactococcus, Rikenella_sp._Marseille_P3215 and Turicibacter and negatively correlated with Parabacteroids, unclassified_Oscillospiraceae, Marvinbryantia, unclassified_Clostridia_vadinBB60_group, unclassified_Erysipelatoclostridiaceae, A2, Roseburia, Rikenellaceae_RC9_gut_group, Acetatifactor and unclassified_Clostridia. The combination of capecitabine and FMT is more effective at preventing CRC than capecitabine alone, as it reverses gut microbial abnormalities and boosts immune responses to CRC.
DOI: 10.17632/62dtcgmfpf.6
title: The combination of capecitabine and fecal microbiota transplantation in colorectal cancer treatment: reversing microbial dysbiosis and regulating the intestinal immune microenvironment

description: The significant economic burden of colorectal cancer (CRC) necessitates the development of innovative therapeutic approaches. Interest in the gut microbiota's role in CRC has increased. Capecitabine, as a chemotherapy, may disrupt the balance of the intestinal microbiota. The study investigated the anticancer effects of capecitabine combined with fecal microbiota transplantation (FMT) in a CRC mouse model caused by azoxymethane and dextran sodium sulfate. FMT was achieved with fecal microbiota from healthy mice through enema. Capecitabine decreased the number and diameter of cancer foci in CRC mice, while FMT supplementation had a more noticeable impact, indicated by increased body weight and survival rate. Capecitabine greatly decreased the abundance of harmful bacteria found in CRC mice. These bacteria included Bacteroides, Enterorhabdus, Monoglobus, Rodentibacter, uncultured_rumen_bacterium, Turicibacter, and Streptococcus. The supplement of FMT more effectively reversed the dysbiosis of the gut microbiota in CRC mice, as demonstrated by the ACE and Chao 1 index, PCoA analysis and enhanced biological pathways. Microbial dysbiosis induced immunological dysfunction in CRC mice, indicated by abnormal immune cell recruitment and excessive cytokine production. Capecitabine treatment reduced immune cell infiltration, including CD3+ T cells, CD4+ T cells, and CD49b+ NK cells, as chemotherapy often suppresses the immune system. The supplement of FMT increased the proportion of CD4+ T cells, CD49b+ NK cells, as well as CD8+ T cells and LY6G+ neutrophils, indicating improved immune responses against CRC. Moreover, capecitabine therapy alone reduced the overexpression of IL1a, IL6, IL12a, IL12b, IL17, IL22, FOXP3, STAT3, IFN-γ, TNF-α, TGF-β, GZMA, CXCR4, OPN, PD-1 and PD-L1. FMT supplementation resulted in a higher immune response to CRC as it had a greater inhibitory effect on the overexpression of inflammatory cytokines and enhanced the production of IL10, IFN-γ and CXCR4. These cytokines were positively correlated with Azospirillum_sp._47_25, Romboutsia, Lactococcus, Rikenella_sp._Marseille_P3215 and Turicibacter and negatively correlated with Parabacteroids, unclassified_Oscillospiraceae, Marvinbryantia, unclassified_Clostridia_vadinBB60_group, unclassified_Erysipelatoclostridiaceae, A2, Roseburia, Rikenellaceae_RC9_gut_group, Acetatifactor and unclassified_Clostridia. The combination of capecitabine and FMT is more effective at preventing CRC than capecitabine alone, as it reverses gut microbial abnormalities and boosts immune responses to CRC.
DOI: 10.17632/62dtcgmfpf.7
title: The combination of capecitabine and fecal microbiota transplantation in colorectal cancer treatment: reversing microbial dysbiosis and regulating the intestinal immune microenvironment

description: The significant economic burden of colorectal cancer (CRC) necessitates the development of innovative therapeutic approaches. Interest in the gut microbiota's role in CRC has increased. Capecitabine, as a chemotherapy, may disrupt the balance of the intestinal microbiota. The study investigated the anticancer effects of capecitabine combined with fecal microbiota transplantation (FMT) in a CRC mouse model caused by azoxymethane and dextran sodium sulfate. FMT was achieved with fecal microbiota from healthy mice through enema. Capecitabine decreased the number and diameter of cancer foci in CRC mice, while FMT supplementation had a more noticeable impact, indicated by increased body weight and survival rate. Capecitabine greatly decreased the abundance of harmful bacteria found in CRC mice. These bacteria included Bacteroides, Enterorhabdus, Monoglobus, Rodentibacter, uncultured_rumen_bacterium, Turicibacter, and Streptococcus. The supplement of FMT more effectively reversed the dysbiosis of the gut microbiota in CRC mice, as demonstrated by the ACE and Chao 1 index, PCoA analysis and enhanced biological pathways. Microbial dysbiosis induced immunological dysfunction in CRC mice, indicated by abnormal immune cell recruitment and excessive cytokine production. Capecitabine treatment reduced immune cell infiltration, including CD3+ T cells, CD4+ T cells, and CD49b+ NK cells, as chemotherapy often suppresses the immune system. The supplement of FMT increased the proportion of CD4+ T cells, CD49b+ NK cells, as well as CD8+ T cells and LY6G+ neutrophils, indicating improved immune responses against CRC. Moreover, capecitabine therapy alone reduced the overexpression of IL1a, IL6, IL12a, IL12b, IL17, IL22, FOXP3, STAT3, IFN-γ, TNF-α, TGF-β, GZMA, CXCR4, OPN, PD-1 and PD-L1. FMT supplementation resulted in a higher immune response to CRC as it had a greater inhibitory effect on the overexpression of inflammatory cytokines and enhanced the production of IL10, IFN-γ and CXCR4. These cytokines were positively correlated with Azospirillum_sp._47_25, Romboutsia, Lactococcus, Rikenella_sp._Marseille_P3215 and Turicibacter and negatively correlated with Parabacteroids, unclassified_Oscillospiraceae, Marvinbryantia, unclassified_Clostridia_vadinBB60_group, unclassified_Erysipelatoclostridiaceae, A2, Roseburia, Rikenellaceae_RC9_gut_group, Acetatifactor and unclassified_Clostridia. The combination of capecitabine and FMT is more effective at preventing CRC than capecitabine alone, as it reverses gut microbial abnormalities and boosts immune responses to CRC.
DOI: 10.34816/efa.archives.1217221
title: Délos-FRV_B16_01-006-Prytanée, vue d'ensemble

description: Référence : FRV_B16_01-006<br />Publication(s) : Inédit<br />Domaine : Architecture<br />
DOI: 10.34816/efa.archives.1217222
title: Délos-FRV_B16_01-007-Naos, vue d'ensemble

description: Référence : FRV_B16_01-007<br />Publication(s) : Inédit<br />Domaine : Architecture<br />
DOI: 10.34816/efa.archives.1217223
title: Délos-FRV_B16_01-008-Angle nord-ouest, vue d'ensemble

description: Référence : FRV_B16_01-008<br />Publication(s) : Inédit<br />Domaine : Architecture<br />